Background: rVIII-SingleChain, a novel recombinant factor VIII (rFVIII), has been designed as a B-domain truncated construct with covalently bonded heavy and light chains, aiming to increase binding affinity to von Willebrand factor (VWF). Preclinical studies confirmed greater affinity for VWF, giving improved pharmacokinetic and pharmacodynamic properties compared with full-length rFVIII.
Aim: To investigate the pharmacokinetics of rVIII-SingleChain and compare them against those of full-length rFVIII.
Methods: This study enrolled 27 patients with severe haemophilia A in the AFFINITY clinical trial programme. After a 4-day washout period, all patients received a single infusion of 50 IU kg(-1) octocog alfa (Advate(®) ); after a ≥4-day postinfusion washout period, they received a single infusion of 50 IU kg(-1) rVIII-SingleChain. Blood samples for pharmacokinetic assessments of each product were collected before infusion (predose) and at 0.5, 1, 4, 8, 10, 24, 32, 48 and 72 h postinfusion for both products.
Results: rVIII-SingleChain had a longer mean half-life (t1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs. 3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively. The mean AUCinf after rVIII-SingleChain infusion was ~35% larger than after octocog alfa. A similar pattern was observed for AUC0-last . No serious adverse events or inhibitors were reported.
Conclusions: rVIII-SingleChain has a favourable pharmacokinetic profile compared with octocog alfa and was well tolerated. The prolonged t1/2 , larger AUC and reduced CL of rVIII-SingleChain may permit longer dosing intervals, thereby improving patient adherence to prophylactic treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hae.12985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study.
J Blood Med
January 2025
Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Purpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. However, interindividual differences affect the half-life and clearance of rFVIII products. The myPKFiT is a web-based medical-device software program for population pharmacokinetic (PK) simulation of FVIII products to guide accurate FVIII doses and dosing intervals.
View Article and Find Full Text PDFEfanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.
Adv Ther
November 2024
Hematology Department, S. Bortolo Hospital, Vicenza, Italy.
Article Synopsis
- The Phase 3 XTEND-1 trial demonstrated that efanesoctocog alfa provides better bleed protection than standard factor VIII (FVIII) replacement therapies for patients with severe hemophilia A.
- A systematic literature review was conducted to compare bleeding outcomes between efanesoctocog alfa and different types of FVIII therapies, using statistical methods to analyze annualized bleeding rates (ABRs).
- Results showed that efanesoctocog alfa was linked to significantly fewer annual bleeds, averaging 2.2 fewer versus extended half-life therapies and 3.6 fewer versus standard therapies.
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review.
Blood Res
August 2024
Department of Pediatrics, Daegu Catholic University Medical Center, 33 Duryugongwon-Ro 17-Gil, Nam-Gu, Daegu, 42472, Republic of Korea.
Article Synopsis
- - The study explored the pharmacokinetics (PK) of factor VIII in Korean patients with moderate-to-severe hemophilia A, aiming to fill a knowledge gap in this specific population.
- - Data was collected from 48 patients treated with octocog alfa and 81 patients treated with rurioctocog alfa pegol, revealing differences in half-lives and how blood type and other factors influence PK profiles.
- - Findings indicate significant variability in FVIII PK among individuals, highlighting the importance of personalizing treatment regimens based on each patient's PK profile for better prophylaxis outcomes.
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A.
Haemophilia
September 2024
Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
Introduction: Lonoctocog alfa is a single-chain factor VIII (FVIII) molecule with high binding affinity to von-Willebrand-factor. While it is well known that its plasma activity is underestimated by one-stage clotting assays (OSCA), there is a lack of knowledge on the post-infusion performance of lonoctocog alfa in global coagulation assays or its potential impact on the haemostatic balance in vivo.
Aim: To characterize lonoctocog alfa versus octocog alfa in pre- and post-infusion samples obtained from patients undergoing repeated investigation of incremental recovery (IR).
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Haemophilia
March 2024
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Introduction: Damoctocog alfa pegol (BAY 94-9027, Jivi®) is an extended half-life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction of damoctocog alfa pegol in Canada in 2020, there have been no reports on routine clinical effectiveness and satisfaction, when switching from a previous FVIII product in Canada.
Aim: To report changes in pharmacokinetics, effectiveness, utilization and patient satisfaction when switching to damoctocog alfa pegol prophylaxis from previous standard half-life octocog alfa (BAY 81-8973, Kovaltry®) treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!